110 related articles for article (PubMed ID: 15914872)
1. Four countries shed light on drug-review policies.
Young D
Am J Health Syst Pharm; 2005 Jun; 62(11):1122-3, 1130. PubMed ID: 15914872
[No Abstract] [Full Text] [Related]
2. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
Morgan SG; McMahon M; Mitton C; Roughead E; Kirk R; Kanavos P; Menon D
Health Aff (Millwood); 2006; 25(2):337-47. PubMed ID: 16522575
[TBL] [Abstract][Full Text] [Related]
3. Globalization of biotechnology and the public health challenges accompanying it.
Malinowski MJ
Albany Law Rev; 1996; 60(1):119-69. PubMed ID: 10170488
[No Abstract] [Full Text] [Related]
4. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
5. [Marketing of pediatric drugs].
Pabst JY
Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
[No Abstract] [Full Text] [Related]
6. Fifth Annual David A. Winston Lecture.
McClellan MB
J Health Adm Educ; 2004; 21(1):3-14. PubMed ID: 15129897
[No Abstract] [Full Text] [Related]
7. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.
Kessler DA; Hass AE; Feiden KL; Lumpkin M; Temple R
JAMA; 1996 Dec; 276(22):1826-31. PubMed ID: 8946904
[TBL] [Abstract][Full Text] [Related]
8. American immunization policies: actions speak louder than words.
Grabenstein JD
Hosp Pharm; 1993 Dec; 28(12):1233-4, 1237-40. PubMed ID: 10130619
[No Abstract] [Full Text] [Related]
9. Pharmacoeconomics comes of age?
Walley T; Breckenridge A
Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
[TBL] [Abstract][Full Text] [Related]
10. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
Rawlins SM
Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
[No Abstract] [Full Text] [Related]
11. Medicine. The intangible value of vaccination.
Rappuoli R; Miller HI; Falkow S
Science; 2002 Aug; 297(5583):937-9. PubMed ID: 12169712
[No Abstract] [Full Text] [Related]
12. Overwhelmed drug regulators seek cure in cooperation.
Laursen L
Nat Med; 2011 Jul; 17(7):753. PubMed ID: 21738129
[No Abstract] [Full Text] [Related]
13. The pricing of pharmaceuticals: an international comparison.
Dickson M
Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
[TBL] [Abstract][Full Text] [Related]
14. ICH3: a report and background.
D'Arcy PF
Adverse Drug React Toxicol Rev; 1996 Jun; 15(2):125-7. PubMed ID: 8836318
[No Abstract] [Full Text] [Related]
15. The United States and Cuba - Turning Enemies into Partners for Health.
Keck CW
N Engl J Med; 2016 Oct; 375(16):1507-1509. PubMed ID: 27797312
[No Abstract] [Full Text] [Related]
16. FDA reorganization inspires hope for better coordination.
May M
Nat Med; 2011 Sep; 17(9):1024. PubMed ID: 21900900
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals and Medical Devices: FDA Oversight.
White RS;
Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-43. PubMed ID: 29361661
[No Abstract] [Full Text] [Related]
18. Asymmetric assessments in valuing pharmaceutical risks.
Viscusi WK; Magat WA; Scharff R
Med Care; 1996 Dec; 34(12 Suppl):DS34-47. PubMed ID: 8969313
[No Abstract] [Full Text] [Related]
19. Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
Herder M; Krahn TM
Healthc Policy; 2016 May; 11(4):70-81. PubMed ID: 27232238
[TBL] [Abstract][Full Text] [Related]
20. Patient access to pharmaceuticals: an international comparison.
Cohen J; Faden L; Predaris S; Young B
Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
